SELVITA S A

Selvita Becomes First CRO to License Medicines Discovery Catapult's Patented Target Engagement Technology

- Selvita has become the first contract research organization to license Medicines Discovery Catapult's Chemical Protein Stability Assay (CPSA), a patented technology designed to accelerate drug candidate identification and prioritization. - The CPSA technology offers a streamlined, single-plate format for assessing target engagement that improves consistency and throughput compared to traditional multi-step assays. - This licensing agreement enables Selvita to integrate the novel technology into its early discovery screening cascades, supporting rapid assessment of drug-target engagement at scales compatible with hit identification campaigns. - The technology uses cell lysates to allow protein screening in native contexts without complex purification workflows, making it applicable across various cellular protein targets and screening stages.